Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells

International Journal of Cancer

Volumn 122, Issue 2, 2008, Pages 274-280

  Jeong, Jee Yeong ^a   Feldman, Laurie ^a   Solar, Peter ^a,b   Szenajch, Jolanta ^a,c   Sytkowski, Arthur J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

^c MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Autocrine; Erythropoietin; Erythropoietin receptor; Ovarian cancer; Paracrine; Signal transduction

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY;

ARTICLE; AUTOCRINE EFFECT; BIOASSAY; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; DNA SEQUENCE; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MITOGENESIS; OVARY CANCER; PARACRINE SIGNALING; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION MAPPING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; DNA RESTRICTION ENZYMES; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; RECEPTORS, ERYTHROPOIETIN; SEQUENCE HOMOLOGY, NUCLEIC ACID; SIGNAL TRANSDUCTION;

EID: 36849059273     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23068     Document Type: Article

References (32)

1. Cerami A. Beyond erythropoiesis: novel applications for recombinant human erythropoietin. Semin Hematol 2001;38(3, Suppl 7):33-9.
2. Sytkowski AJ. Erythropoietin: blood, brain and beyond. Weinheim: Wiley-VCH, 2004.
3. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70:246-50.
4. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-5.
5. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and Stat5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 2006; 66:135-45.
6. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998;273:25381-7.
7. Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, Mori S, Matsuo T, Nakamura Y. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001;106(2, Suppl 2):215-22.
8. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagao M, Sasaki R, Nakamura Y. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001;84:836-43.
9. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002;23:1797-805.
10. Showers MO, Moreau JF, Linnekin D, Druker B, D'Andrea AD. Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation. Blood 1992;80:3070-8.
11. Soule HD, Maloney TM, Wolman SR, Peterson WD, Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.
12. Tait L, Soule HD, Russo J. Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6087-94.
13. Wilson JK, Sargent JM, Elgie AW, Hill JG, Taylor CG. A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J Cancer 1990;62:189-94.
14. Fanning J, Biddle WC, Goldrosen M, Crickard K, Crickard U, Piver MS, Foon KA. Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. Gynecol Oncol 1990;39:119-22.
15. Huxham IM, Barlow AL, Lewis AD, Plumb J, Mairs RJ, Gaze MN, Workman P. Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780ad) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis. Int J Cancer 1994;59:94-102.
16. Spinner DM, Brandstetter T, Kiechle-Schwarz M, Du Bois A, Angel P, Bauknecht T. C-jun expression and growth stimulation in human ovarian carcinoma cell lines following exposure to cytokines. Int J Cancer 1995;63:423-7.
17. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt M-AV, Bast RC, Jr, Mills GB. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 1999;5:3704-10.
18. Yoshida H, Cheng W, Hung J, Montell D, Geisbrecht E, Rosen D, Liu J, Naora H. Lessons from border cell migration in the Drosophila ovary: a role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci USA 2004;101:8144-9.
19. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, Koeffler HP. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005;11:7243-54.
20. Muthukumaran N, Miletti-Gonzalez KE, Ravindranath AK, Rodriguez-Rodriguez L. Tumor necrosis factor-alpha differentially modulates CD44 expression in ovarian cancer cells. Mol Cancer Res 2006; 4:511-20.
21. Wognum AW, Lansdorp PM, Eaves CJ, Krystal G. Use of a sensitive bioimmunoabsorbent assay to isolate and characterize monoclonal antibodies to biologically active human erythropoietin. Blood 1988; 71:1731-7.
22. Yoshimura A, D'Andrea AD, Lodish HF. Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. Proc Natl Acad Sci USA 1990;87:4139-43.
23. Bailey SC, Feldman L, Romanowski RR, Davis KL, Sytkowski AJ. Antipeptide antibodies as probes of the recombinant and endogenous murine erythropoietin receptors. Exp Hematol 1993;21:1535-43.
24. Yet MG, Jones SS. The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin. Blood 1993;82:1713-9.
25. Leyland-Jones B. BEST investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
26. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
27. Henke M, Pajonk F. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:993.
28. Luksenburg H. Evolving safety issues associated with erythropoietin products. FDA Oncologic Drugs Advisory Committee, 2004.
29. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-9.
30. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307:999-1007.
31. McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Bell A, Verma A. Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol 2005;99:571-7.
32. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-82.